+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the effects of lower dose-intensity continuous renal replacement therapy CRRT compared to the standard dose-intensity in critically ill patients with acute kidney injury AKI who need dialysis in the intensive care unit ICU. This trial aims to determine if a lower dose of CRRT is at least as effective as the current standard and whether it can shorten the duration of therapy and improve kidney recovery. The study builds on previous findings suggesting that lower dose-intensity may reduce complications and costs without worsening outcomes. Participants will be assigned to one of two groups the intervention group receiving low dose-intensity CRRT at 10-15 mLkghr, or the control group receiving standard dose-intensity CRRT at 25-30 mLkghr, consistent with international guidelines. Both groups will receive continuous dialysis therapy during their ICU stay. This pilot trial will help inform a larger future trial to guide clinical practice in CRRT dosing. During the study, participants will be closely monitored for the dose of CRRT delivered, adherence to the prescribed dose, and kidney function recovery. Researchers will also collect data on feasibility measures such as consent and recruitment rates over approximately one year. The primary outcome is the difference in delivered CRRT dose-intensity over about one month, with follow-up assessments continuing up to 90 days. The total study duration extends until June 2027.

Age: 18Years +All GendersPhase Not Applicable
10 locations
R

Actively Recruiting

Researchers are evaluating different partial wrist fusion techniques for adults with post-traumatic wrist arthritis, specifically those with stage II or III scapholunate advanced collapse SLAC or scaphoid nonunion advanced collapse SNAC. This randomized clinical trial compares two surgical methods to determine which provides better clinical and radiographic outcomes. The study is designed as a multi-center, double-blind, prospective trial to guide surgical decisions for patients needing wrist fusion surgery. Participants will be randomly assigned to one of two groups Group A will undergo four-corner arthrodesis, where the scaphoid is removed and the lunate, capitate, triquetrum, and hamate bones are fused. Group B will have partial wrist arthrodesis with triquetral excision, where both the scaphoid and triquetrum are removed and either three-corner or capitolunate fusion is performed. The study includes pre-operative assessment and follow-ups at 6 weeks, 3, 6, and 12 months post-surgery. During the study, participants will complete grip strength tests, wrist range of motion measurements, and various questionnaires assessing pain and wrist function at multiple points. Radiographs and complication tracking will also be done at each visit. The primary outcome is grip strength compared between groups over 12 months. Analysis will consider age and sex, using statistical modeling to compare results, aiming to inform which surgical technique best preserves wrist function and patient-reported outcomes.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
5 locations
S

Actively Recruiting

This trial evaluates Tezepelumab, a newly approved medication for adults with severe asthma who experience sudden worsening symptoms that require emergency care. The study aims to determine if starting Tezepelumab in the Emergency Department can help control asthma symptoms and reduce repeated visits or the need for steroid treatments. Adults with a history of asthma and recent exacerbations are the focus, and the trial compares Tezepelumab to a placebo in a phase 4 randomized, double-blinded study. Participants are randomized to receive either Tezepelumab 210 mg or a matching placebo through subcutaneous injections every four weeks for 90 days. After this period, all participants enter an open-label extension where they receive Tezepelumab for an additional 90 days. The study tracks the proportion of patients returning to the Emergency Department for asthma exacerbations during the first 90 days and again by day 180, while also monitoring other asthma control measures and drug safety. During the study, participants undergo regular assessments including asthma control questionnaires, lung function tests, and blood tests to measure inflammatory markers. The primary outcome is the rate of moderate and severe asthma exacerbations by day 90. Safety and tolerability of the medication are monitored throughout, and participants are followed for a total of 180 days. This research is sponsored by the University of Alberta and aims to provide important data on managing severe asthma in emergency settings.

Age: 18Years - 55YearsAll GendersPhase 4
2 locations
S

Actively Recruiting

Researchers are evaluating the use of esophageal pressure-guided positive end-expiratory pressure PEEP titration in patients with respiratory failure who have a body mass index BMI of 30 kgm2 or higher and require mechanical ventilation. This randomized controlled feasibility study aims to determine if a larger definitive trial is practical and to compare the effects of this specialized PEEP titration method against standard care on respiratory mechanics and clinical outcomes. The trial is conducted in a hospital setting and focuses on patients with obesity undergoing invasive ventilation. Participants will be randomly assigned to one of two groups one receiving esophageal pressure-guided PEEP titration, where an esophageal balloon catheter is placed within 4 hours after randomization to guide PEEP adjustments targeting an end-expiratory transpulmonary pressure of 0-2 cmH2O with higher targets allowed for severe hypoxemia, and the other receiving standard care PEEP management without esophageal monitoring. The esophageal catheter is repositioned and PEEP reassessed twice daily and removed before extubation or after 28 days. Standard care follows institutional guidelines, including ARDSNet tables for ARDS patients. During the study, participants will have continuous monitoring of respiratory parameters, including PEEP levels, driving pressures, oxygenation ratios, days free of mechanical ventilation, ICU-free days, and mortality up to hospital discharge or 30 days. The primary outcome is the feasibility of conducting a larger trial over 14 months. Safety limits on pressures and hemodynamic stability will be monitored. The total study duration includes assessments in the first 7 days and follow-up until hospital discharge or 30 days after enrollment.

Age: 18Years +All GendersPhase 2
2 locations